Drug Interaction Between Augmentin and Allopurinol
The combination of amoxicillin-clavulanate (Augmentin) and allopurinol significantly increases the risk of skin rashes, with the incidence rising from approximately 6% to 14% when both drugs are used together. This interaction is well-documented in FDA labeling and should be anticipated when prescribing these medications concurrently.
The Core Interaction
The FDA label for Augmentin explicitly warns that "the concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone" 1. While the label notes there are no specific data with Augmentin and allopurinol administered together, the mechanism appears related to either allopurinol itself or the hyperuricemia present in these patients 1. The allopurinol FDA label similarly confirms that "the frequency of skin rash among patients receiving ampicillin or amoxicillin concurrently with allopurinol tablets has been reported to be increased" 2.
Research data quantifies this risk precisely: among hospitalized patients receiving ampicillin alone, 5.9% developed rashes, but this jumped to 13.9% when ampicillin and allopurinol were given together 3. This represents more than a doubling of rash incidence.
Clinical Management Strategy
When Both Drugs Are Necessary:
- Counsel patients explicitly about the increased rash risk before starting therapy
- Instruct patients to discontinue both medications immediately if any skin rash develops and contact you urgently 2
- Monitor closely during the first 3 weeks of concurrent therapy, as most drug-related rashes manifest within 21 days of exposure 3
- Be vigilant for severe reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome, which can be life-threatening 2
Risk Mitigation Considerations:
The risk is particularly elevated in patients with:
- Renal impairment (increases both allopurinol-related rash risk and drug accumulation) 2
- Recent initiation of allopurinol therapy
- Higher allopurinol doses
Important Caveats
This interaction does NOT contraindicate concurrent use - the drugs can be prescribed together when clinically necessary. However, the heightened rash risk demands:
- Clear medical justification for using both agents simultaneously
- Patient education about warning signs
- Close monitoring during early treatment phases
- Immediate discontinuation protocols if rash develops
The mechanism remains incompletely understood - it may relate to allopurinol itself, the underlying hyperuricemia, or altered immune responses in gout patients 1. Regardless of mechanism, the clinical reality of doubled rash incidence is well-established.
Additional Safety Notes:
Beyond rashes, be aware that allopurinol can cause serious hypersensitivity reactions including fever, eosinophilia, hepatic necrosis, and renal failure 2. When initiating allopurinol (especially with concurrent Augmentin), start at low doses (≤100 mg/day, lower in renal impairment) and titrate gradually 4. This approach reduces overall hypersensitivity risk while maintaining the option for concurrent antibiotic therapy when needed.
The bottom line: Use this combination when clinically indicated, but warn patients about the substantially increased rash risk and establish clear protocols for immediate drug discontinuation if skin reactions occur.